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ABSTRACT
Tardive dyskinesia (TD) is a movement disorder associated with dopamine receptor
blocking medications. Recommended treatments for TD include discontinuing the
causative agent, adding vesicular monoamine transporter 2 (VMAT2) inhibitors, or
adding vitamin B6. We present a 66-year-old Caucasian male with bipolar I disorder who
developed TD while on lithium and quetiapine, having been euthymic on this regimen
for three years. He was initially treated with 1200 mg B6 daily, which failed to improve
his TD and was associated with a depressive episode. He switched to valbenazine 40
mg daily, which improved his TD and concurrently his mood, but months later, the
TD symptoms worsened again. Our case adds to the literature by demonstrating that
some patients with TD will not respond to vitamin B6. To our knowledge, ours is the
first case suggesting the association of high-dose vitamin B6 with depression. This case
also demonstrates that response to valbenazine may not last, and further studies are
needed.
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INTRODUCTION
Tardive dyskinesia (TD) is a movement disorder that
may be severe and can involve the mouth, tongue,
jaw, trunk, and extremities. It is most commonly
caused by dopamine receptor blocking medications.1
The annual incidence of TD is 3.9% overall for patients
on long-term, second-generation antipsychotics.2
Common treatments for TD include discontinuing
the offending agent or adding dopamine-depleting
VMAT2 inhibitors such as valbenazine.3 More
recently, high-dose pyridoxine (vitamin B6) has also
been studied as a treatment for TD.4 Vitamin B6 is
metabolized to Pyridoxyl-5-PO4, which is a coenzyme
that participates in the process of synthesizing
dopamine, epinephrine, norepinephrine, serotonin,
melatonin, and GABA, the latter of which has been
shown to correlate with measured levels in the brain
as a function of TD symptoms.5,6
A study by Lerner et al. showed vitamin B6 400
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mg daily reduced TD symptoms by 68.6% per the
Extrapyramidal Symptoms Rating Scale (ESRS) after
four weeks compared to baseline.7 A double-blind,
placebo-controlled crossover study also by Lerner
et al. showed statistically significant improvement
of TD symptoms in patients with schizophrenia and
schizoaffective disorder on vitamin B6 1200 mg
daily.8 Several similar studies reviewed by Umar et
al. showed varying responses to vitamin B6, from
having no significant changes to a 77% reduction in
symptoms.9
We present a case of a patient with bipolar I disorder
and TD who did not respond to high-dose vitamin
B6 therapy but did develop an episode of depression
during the B6 treatment period. To our knowledge,
ours is the first case suggesting a possible association
of high-dose vitamin B6 with depression. This
suggests the need for further studies into factors
that might predict a positive response to high-dose
vitamin B6 and caution to follow mood symptoms
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in patients receiving this treatment. For historical
clarification, our patient was not approved by
insurance for the use of valbenazine at the onset of
TD symptoms, hence why vitamin B6 was trialed first.
Upon obtaining valbenazine some months later, the
patient initially responded to the VMAT2 inhibitor
with an improvement of TD symptoms; however,
symptoms worsened on the same regimen after
several months. Therefore, this case also suggests
that longer-term studies are needed on the efficacy
of valbenazine.
CASE PRESENTATION
A 66-year-old Caucasian male with bipolar I disorder
(whose most recent depressive episode and alcohol
use disorder were in full remission) and tardive
dyskinesia was referred to our clinic. The patient’s
bipolar disorder had been stable for over three years
on lithium 300 mg twice daily and quetiapine 200
mg nightly.
At his first visit, he reported a history of depressive
and manic episodes with hallucinations and alcohol
use at the time of his diagnosis in his thirties. He had
several psychiatric hospitalizations in the past but
had been euthymic for over 3 years and sober for 30
years. He also had mild tremors of both hands and
dyskinesias of the face and mouth, which he was
aware of but were not bothersome. He continued
treatment with lithium 300 mg bid and quetiapine
200 mg qhs. Lithium levels were monitored regularly
and ranged from 0.5-0.7 mEq/L throughout
treatment, never showing toxicity or variation from
his established sufficient levels.
At the next three-month appointment, he reported
an increasing right arm tremor. His oral, facial,
and lingual manifestations were also noted to
be increased. The patient did not wish to alter
medication as his mood was stable, and the tremors
were not bothersome. His Abnormal Involuntary
Movement Scale (AIMS) score was 11, with an overall
severity of 2 (mild).
Six months into treatment, the patient reported a
significantly increased tremor and dyskinetic oral
movements, having shattered nine of his teeth. He
required a bite guard to prevent further damage
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and was prescribed pain medication and antibiotics.
His AIMS score was 9, with an overall severity of 3
(moderate). Despite his worsening physical condition,
the patient reported a stable mood. He was started
on vitamin B6 1200 mg daily as a substitute to treat
his TD.
Three months after starting vitamin B6, the patient
returned to the clinic with a significantly depressed
mood. He stated the onset of depressive symptoms
coincided with starting the vitamin B6 supplement
and did not change after completing the course
of antibiotics and pain medication prescribed by
dentistry. He did not disclose the addition of any
other supplements or medications. He reported
decreased energy, decreased interest in hobbies,
increased sleep, decreased appetite, and lower
self-worth. He denied suicidal ideations. No other
changes in social history or life stressors were noted.
In addition, there was no improvement in his TD from
the B6 therapy. His AIMS score was 9, with an overall
severity of 3 (moderate). The patient was instructed
to discontinue vitamin B6 at that time and start
valbenazine 40 mg daily.
Two months after starting valbenazine, the patient
reported up to a 50% decrease in bruxism and arm
movements. He also reported an improvement in his
mood and no longer felt depressed. His AIMS score
was reduced to 7 with an overall severity of 2 (mild).
At the next visit, he reported worsening hand
tremors and oral dyskinesia. At this time, his AIMS
score was 11, with overall severity of 3 (moderate).
He did not want to stop the valbenazine despite the
relapse of TD, and his bipolar depression remained in
remission.
DISCUSSION
This case is presented due to the relapse of
depression our patient exhibited while on high-dose
vitamin B6. The dosage of B6 1200 mg was chosen
based on the study by Lerner et al. published in 2007,
in which 50 hospitalized patients with schizophrenia
or schizoaffective disorder with TD were given daily
doses of 1200 mg and compared with a placebo.8
They saw statistically significant improvements in
ESRS scores of the patients treated with the vitamin
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vs. the placebo group. They also noted the study
revealed no side effects in patients on the high
dose of B6. Lerner and his group have published
several studies on vitamin B6 and tardive dyskinesia;
however, they conclude that while efficacious in their
small, specific patient samples, the mechanism of
action has yet to be determined.8
In looking at other studies of vitamin B6 or its
metabolically active form, pyridoxal 5’ phosphate,
it is proposed that antioxidant properties may
improve TD if the pathogenesis is due to free radical
formation.5 Other studies have shown that low levels
of folate or pyridoxine in the brain correlate with
depression, giving rise to more evidence that major
depressive disorder or bipolar disorder patients
may benefit from vitamin B6.10 However, a Cochrane
review of literature on using pyridoxal 5’ phosphate
to treat neuroleptic-induced TD in patients with
schizophrenia found little quality evidence to
support the drug. They cited small samples, limited
follow-up periods, and few studies, with a need for
more future research.4
While clinical trials for patients are hard to come by,
Jeanclos et al. published an interesting experiment
in Molecular Basis of Disease in January 2019,
which showed that increasing the level of pyridoxal
5’ phosphate in the CNS of mice did not affect
dopamine, serotonin, epinephrine, or glutamate.
Instead, the level of GABA was increased by 20%
or more. This led to improved spatial learning and
memory but decreased motor performance and
induced anxiety within the mice.11 It has been shown
that GABA plays a prominent role in movement
disorders, but its ability to be modulated by the gene
for pyridoxal phosphatase is a novel finding.12
Several connections and contradictions to our case
are noted in the literature. In the Lerner et al. trials,
patients showed statistically significant improvement
of TD without any side effects reported. Not only
did our patient not benefit from vitamin B6, but he
also developed a depressive episode after 3 years
of euthymia while on consistent lithium dosing
and levels obtained during treatment. Our patient
also had the diagnosis of bipolar I disorder versus
schizophrenia or schizoaffective disorder. Another
speculation is that our patient’s mood disorder
predisposed him to have a depressive episode upon
MARSHALL JOURNAL OF

MEDICINE
™

Expanding Knowledge to Improve Rural Health.

the disruption of vitamin B6 levels, or his depression
was coincidental and independent of treatment
changes.
Tardive dyskinesia is a challenging and objective
phenomenon to measure. While using the ESRS or
AIMS, points may be assigned differently between
physicians and their observations. This was notably
the case with our patient, as he was seen by
multiple psychiatry residents who performed the
AIMS separately. Although AIMS was created by
the National Institute of Mental Health (NIMH), this
method has inconsistencies among different raters
and leads to difficulty interpreting the efficacy of
treatments.13
While our case provides an example of differing
interpretations by physicians, we cannot discredit
the subjective experience reported by the patient.
On the trial of vitamin B6, our patient did not report
improvements of his TD, but after 2 months on
valbenazine, he reported a 30-50% decrease in
bruxism and tremors. However, five months later,
he reported worsening symptoms on the same
medication that previously helped. The Food and
Drug Administration approved the VMAT2 inhibitor
valbenazine based on 3 placebo-controlled, 6-week
clinical trials.14 However, as demonstrated with
our patient, TD often requires a treatment period
longer than 6 weeks. Published in 2019, KINECT 4
was a phase 3 study on valbenazine, which followed
patients through week 48 of treatment.15 Neurocrine
Biosciences reported that 53.7% of patients taking
40 mg of valbenazine daily through the end of
the study had continuous improvements of TD.
While this number is a majority, the sample size of
participants at week 48 was n=20, meaning this
statistic accounted for only about 11 patients.16
This failure of valbenazine to consistently provide
symptom management for our patient, as well as
more recent studies with limited power, suggests the
need for continued studies on the response of TD to
valbenazine.
Overall, our case report contributes to the literature
by raising the possibility that high-dose vitamin B6
treatment of TD can be associated with the onset
of depression in a patient with bipolar disorder.
While many studies have reported improvements
in dyskinetic movements treated with vitamin B6,
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our case suggests the need for further research on
the etiology and treatment of TD, the mechanism of
action of vitamin B6 in the brain, and other methods
of treatment for neuroleptic-induced TD. Finally,
we provide an example of a patient who initially
appeared to improve on valbenazine but later
had a relapse of TD symptoms. Further studies of
valbenazine are needed to understand the long-term
outcomes of this treatment.
CONCLUSION
The presented case adds to the limited literature
regarding the use of vitamin B6 to treat
antipsychotic-induced tardive dyskinesia and reveals
inefficacy and associated depression relapse. This
study also suggests the need for further research on
the long-term use of VMAT2 inhibitors in treating
tardive dyskinesia.
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